Quick Takeaways:
- Zenex Animal Health has acquired a majority stake in VievePharm, strengthening its push into the global “naturals” segment. The deal establishes a manufacturing and commercial hub in Western Europe, marking a key step in Zenex’s international expansion strategy
- VievePharm brings expertise in phytogenic formulations across livestock, equine, and pet care, along with a GMP+, FSA, and Skal-certified facility serving 60+ customers in 25+ countries. The acquisition complements Zenex’s Ayurvedic portfolio (post-Ayurvet deal) and adds advanced bolus manufacturing capabilities for minerals, vitamins, and udder health solutions
- Strategically, the deal enhances Zenex’s access to the European market amid rising demand for antibiotic alternatives, supported by EU targets to cut veterinary antibiotic use. Leveraging VievePharm’s distribution network, Zenex aims to scale exports while combining R&D, natural product expertise, and global reach to deliver sustainable, science-backed animal health solutions
Why It Matters?
The VievePharm deal gives Zenex a certified Western European manufacturing and sales base plus advanced bolus technology, accelerating its shift from an India‑focused player to a global naturals-led animal health company aligned with EU antibiotic‑reduction targets.
By combining Ayurvet’s Ayurvedic range with VievePharm’s phytogenic portfolio and distribution into 25+ countries, Zenex is building a differentiated, science‑backed “antibiotic‑alternative” platform that can ride growing demand for sustainable nutrition and udder health solutions across Europe and emerging markets.
Source: Zenex
